Ligand Receives FDA Orphan Designation for Captisol-Enabled Topiramate Injection

Ligand Pharmaceuticals Incorporated LGND announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for its proprietary Captisol-enabled™ Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate. “The granting of orphan designation for Ligand's Captisol-enabled Topiramate program is an important step in the future of this potentially life-saving therapeutic, and should provide an additional layer of market exclusivity for the program,” commented Matthew W. Foehr, Executive Vice President and Chief Operating Officer of Ligand. “In Phase 1 trials in healthy volunteers and patients at the University of Minnesota, this product See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsGuidanceContractsManagementGlobalBiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!